bioihbjkbjnl/mcl2 huggingface dataset:
Effectiveness of Mat Pilates and Aerobic Training on Fatigue and Depression
Condition: Post Partum Depression
MeSH terms: Depression, Postpartum; Fatigue; Depression; Depressive Disorder
Study type: Interventional

Summary: 
      The aim is to see fatigue and depression levels in postpartum females and to evaluate ho two
      well-known exercises, Mat Pilates and Aerobic training can help to reduce the fatigue levels
      in postpartum females
    

Detailed description: 
      The aim is to see fatigue and depression levels in postpartum females and to evaluate ho two
      well-known exercises, Mat Pilates and Aerobic training can help to reduce the fatigue levels
      in postpartum females. In this study, the researcher will also compare the effects of Mat
      Pilates and Aerobic training on fatigue and depression levels among postpartum females.
    

Intervention name(s): Pilates training; Aerobic Training
Intervention type(s): Other; Other
Intervention description(s): Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.; WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week
SITTING EERCISES:
Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times
BALANCE EXERCISES:
Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.
Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Depression; Fatigue; low intensity Aerobic training; Mat-Pilates
A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects
Condition: COVID-19
Study type: Interventional
Phase: Phase 1

Summary: 
      This study is a randomized, open, single-dose, two-sequence, two-cycle, double-cross design
      bioequivalence study.

      32 eligible subjects will be randomly assigned to TR group and RT group in a 1:1 ratio.
      Subjects in the TR group will take the test preparation (T) 200 mg/ pill × 1 pill on day 1
      (D1) and the reference preparation (R) 200 mg/ pill × 1 pill on day 8 (D8). The sequence of
      medication in RT group is reversed from TR group. Wash for at least 7 days between doses.

      Screening was performed within 28 days prior to initial dosing, and all eligible subjects
      were admitted to the clinical research Center 1 day prior to Cycle 1 dosing (D-1) and
      discharged on day 10 of the study (D10) after completing Cycle 2 PK blood collection,
      corresponding safety examination, and evaluation. On the 14th day of the study (± 1 day), the
      clinical research center was returned for follow-up to further evaluate the safety and
      tolerability of the subjects.
    

Detailed description: 
      This study is a randomized, open, single-dose, two-sequence, two-cycle, double-cross design
      bioequivalence study.

      32 eligible subjects will be randomly assigned to TR group and RT group in a 1:1 ratio.
      Subjects in the TR group will take the test preparation (T) 200 mg/ pill × 1 pill on day 1
      (D1) and the reference preparation (R) 200 mg/ pill × 1 pill on day 8 (D8). The sequence of
      medication in RT group is reversed from TR group. Wash for at least 7 days between doses.

      The trial drug STI-1558 should be taken with approximately 240 ml of water after fasting
      overnight for at least 10h. Except for drinking water, water should be prohibited for at
      least 1h before and after administration, and fasting should be at least 4h after
      administration. Test drugs (T and R) must be swallowed whole and not chewed, crushed or
      separated. In order to ensure the subject's compliance with the medication procedure, the
      staff should check the subject's mouth after taking the medication.

      Screening was performed within 28 days prior to initial dosing, and all eligible subjects
      were admitted to the clinical research Center 1 day prior to Cycle 1 dosing (D-1) and
      discharged on day 10 of the study (D10) after completing Cycle 2 PK blood collection,
      corresponding safety examination, and evaluation. On the 14th day of the study (± 1 day), the
      clinical research center was returned for follow-up to further evaluate the safety and
      tolerability of the subjects.
    

Intervention name(s): STI-1558
Intervention type(s): Drug
Intervention description(s): STI-1558 test preparation and reference preparation
Other intervention name(s): An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
Condition: Meningococcal Immunisation (Healthy Volunteers)
Study type: Interventional
Phase: Phase 3

Summary: 
      Primary Objective:

      To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A,
      C, Y, and W following the administration of a single dose of Meningococcal Polysaccharide
      (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)
      compared with those observed following the administration of a single dose of Meningococcal
      (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®
      vaccine).

      Secondary Objective:

      Immunogenicity: To describe the antibody responses to the meningococcal serogroups A, C, Y,
      and W before and 30 days (+14 days) after vaccination with MenACYW Conjugate vaccine or
      Menactra®.

      Safety: To describe the safety profile of MenACYW Conjugate vaccine and that of Menactra®.
    

Detailed description: 
      The duration of each participant's participation in the study was approximately 30 to 44
      days.
    

Intervention name(s): Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine); Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Intervention type(s): Biological; Biological
Intervention description(s): Pharmaceutical form: Liquid solution Route of administration: IM; Pharmaceutical form: Liquid solution Route of administration: IM
Other intervention name(s): Menactra®
Intervention MeSH terms: Vaccines
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
A Clinical Study on the Combined Magnetic and Oxygen Treatment for Bell's Palsy
Condition: Bell's Palsy
MeSH terms: Bell Palsy; Facial Paralysis; Paralysis
Study type: Interventional

Summary: 
      The aim of this clinic trial is to testify the efficacy of using new and noninvasive therapy,
      called simultaneous "Magnetic and Oxygen Treatment along Meridians and Collaterals" (MOMC),
      to treat Bell's Palsy.
    

Detailed description: 
      Between June 1998 and January 2005, a total of 3002 subjects with BP were evaluated, 882
      patients fulfilled the inclusion criteria and entered the study.

      Patients were randomly assigned to either the prednisone-valacyclovir group(group 1) or the
      magnetic-oxygen group(group 2) . Among the 882 patients completing the study,825 patients in
      group 1 received prednisone, given as a single dose of 40 mg daily for 5 days; the dose will
      then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking
      valacyclovir 400 mg in three doses daily for 10 days. 57 patients in group 2 received
      magnetic-oxygen treatment:MOMC treatment was given as daily 20 min section for 10 days with
      2~3 days of intermission between;Oxygen therapy was given simultaneously at a flow rate of
      2~3.0 L / min for the same duration during all acupuncture sections.

      Clinical evaluation for the severity of paralysis was performed immediately before and after
      the treatment using the facial nerve grading (FNG) scores of House and Brackmann system.
    

Intervention name(s): prednisone and valacyclovir treatments; Magnetic and Oxygen Treatment
Intervention type(s): Drug; Device
Intervention description(s): patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.; MOMC treatment was given as daily 20 min section for 10 days with 2~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2~3.0 L / min for the same duration during all acupuncture sections.
Other intervention name(s): prednisone and valacyclovir
Intervention MeSH terms: Valacyclovir; Prednisone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: magnetic; oxygen; Bell's Palsy; acupuncture
Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Disease
Condition: Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Patients
MeSH terms: Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease
Study type: Observational

Summary: 
      Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease at a
      global scale and is strongly associated with the obesity and metabolic syndrome . It is
      recognized as a hepatic manifestation of the metabolic syndrome, and characterized by lipid
      infiltration in the hepatocytes. NAFLD comprises a range of diseases from simple steatosis to
      non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and may progress to hepatocellular
      carcinoma (HCC) .

      The worldwide prevalence of NAFLD is estimated to be 24% while it is reported to have much
      higher incidence in patients with metabolic syndrome and type 2 diabetes (T2D) (5). The
      mortality rate and the number of liver transplantations owing to NAFLD and NASH are
      increasing, making it the second leading cause of liver transplant in the United States .

      Tow significant metabolic abnormalities commonly linked to NAFLD are insulin resistance (IR)
      and increased supply of fatty acids to the liver . Chronic liver diseases (CLD), including
      NAFLD, are commonly associated with nutrient and vitamins deficiencies such as those of
      vitamins D and A (8,9).

      Almost all studies documenting vitamin A status in metabolic syndrome (MetS) report
      reductions in serum retinol, retinoic acid, and/or β-carotene that are inversely correlated
      with MetS features, including obesity, insulin resistance, glucose intolerance, and
      hypertriglyceridemia . In line with these observations, inadequate serum retinol levels
      (<1.05 μmol/L) were found in 11-36% of morbidly obese adults with ultrasonography-proven
      NAFLD, and a significant association between low retinol levels and insulin resistance (IR)
      was found . Moreover, serum retinol levels were inversely associated with body mass and serum
      transaminases in patients with NAFLD, suggesting a link between retinol inadequacy and
      development of disease.

      The liver plays a critical role in lipid metabolism by taking up serum free fatty acids (FFA)
      that are involved in the synthesis, storage, and transport of lipid metabolites. The
      accumulation of excess triacylglycerol (TG) within the liver due to the entry of excess FFA
      from the obese adipose tissue due to increased lipolysis leads to the development of
      non-alcoholic fatty liver diseases (NAFLD) .
    


Observational model: Case-Control
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        This hospital based case control study will be conducted on 110 patients who attend to
        Tropical Medicine and Gastroenterology outpatient clinic, Sohag University Hospital in a
        period of 6 months. Participants will be classified into NAFLD group and control group.
A New Method of Muscle Strength Testing Using a Quantitative Ultrasonic Technique and a Convolutional Neural Network
Condition: Muscle Disorder
MeSH terms: Muscular Diseases
Study type: Observational [Patient Registry]

Summary: 
      In addition to muscle thickness and average echo intensity, this study aimed to use
      quantitative ultrasonic technology to increase the number of related parameters of power
      Doppler ultrasonography measured to describe the number, quality, and recruitment level of
      muscles. In addition, this method was compared with the existing muscle strength testing
      methods. Image recognition was performed using the traditional multivariate linear regression
      statistical method and the AI convolutional neural network algorithm to investigate the
      application of quantitative ultrasonic technology for direct evaluation of muscle strength in
      clinical practice.
    

Detailed description: 
      Collection of all quantitative ultrasonic data was performed by one ultrasound physician. The
      Aixplorer® series color ultrasonic diagnostic instrument of Supersonic Imagine (France) and
      an L15-4 linear array probe were used. The medial head of the quadriceps muscle was measured.
      The subjects wore short pants that settled above the knees. Tight pants were avoided to
      prevent impaired venous return, which can affect the power Doppler ultrasonography result.
      The subjects did not exercise within half an hour before testing. Two-dimensional images of
      the subjects' muscles were collected in a quiet resting state and used to measure muscle
      thickness and the average echo intensity. The power Doppler images were used to measure the
      level of muscle hyperemia. The measurements were performed in the 0° knee extension position
      and the most prominent part of the medial head of the quadriceps muscle was measured by the
      ultrasound physician using visualization. The probe angle was perpendicular to the trajectory
      of the muscle bundle, and the measurement was performed with the muscle in a relaxed state.
      After the measurements, the knee was restrained to complete the isokinetic muscle strength
      test. When testing of the last group was completed, the knee was released immediately. The
      two-dimensional image and the power Doppler image at the same location were captured and the
      image acquisition time was no more than 3 s.
    

Intervention name(s): quantitative ultrasonic technique
Intervention type(s): Diagnostic Test
Intervention description(s): Collection of all quantitative ultrasonic data was performed by one ultrasound physician
Observational model: Other
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        This study recruited 80 volunteers including 54 healthy volunteers, 24 unilateral
        quadriceps atrophy patients and 2 bilateral quadriceps atrophy patients
An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol
Condition: NASH
Study type: Interventional
Phase: Phase 1

Summary: 
      A two-part open-label study to assess the absolute bioavailability of aramchol and the mass
      balance recovery, metabolite profile and identification of metabolite structures for
      [14C]-aramchol in healthy male subjects
    

Detailed description: 
      A two-part open-label study to assess the absolute bioavailability of aramchol and the mass
      balance recovery, metabolite profile and identification of metabolite structures for
      [14C]-aramchol in healthy male subjects.

      A subject was considered evaluable in Part 1 if they provided PK samples for up to a minimum
      of 120 h after first investigational medicinal product (IMP) administration. A subject was
      considered evaluable in Part 2 if they provided biological samples for up to a minimum of 144
      h after IMP administration or demonstrated >90% mass balance recovery, or <1% of the
      administered dose eliminated in excreta for 2 consecutive days, whichever was sooner.
    

Intervention name(s): Aramchol
Intervention type(s): Drug
Intervention description(s): Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
Other intervention name(s): Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid)
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Efficacy of Repaglinide in Subjects With Type 2 Diabetes
Condition: Diabetes; Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 4

Summary: 
      This trial is conducted in Europe. The aim of this trial is to compare the efficacy of
      repaglinide to glyburide and placebo on hepatic glucose metabolism in subjects with type 2
      diabetes.
    


Intervention name(s): repaglinide; glyburide; placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): 1 mg before each main meal on three separate dosing visits separated by a wash-out period; 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period; Before each main meal on three separate dosing visits separated by a wash-out period
Intervention MeSH terms: Glyburide; Repaglinide
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 2

Summary: 
      B2611003 is designed to study how safe and effective an investigational medication
      (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6
      treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug,
      and another treatment will be placebo, which does not contain active ingredient.
    


Intervention name(s): Placebo; 25 mg PF-04991532; 75 mg PF-04991532; 150 mg PF-04991532; 300 mg PF-04991532; Sitagliptin 100 mg
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): Tablets (n=4), 0 mg twice daily for 84 days; Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days; Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days; Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days; Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days; Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
Intervention MeSH terms: Nicotinic Acids; Sitagliptin Phosphate; 6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Phase 2; safety and efficacy study with PF-04991532; Type 2 diabetes
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
Condition: Diabetes; Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 1

Summary: 
      This trial is conducted in the United States of America (USA). The aim of this trial is to
      compare repaglinide and metformin administered as an individual tablets with repaglinide and
      metformin administered as a combination tablet.
    


Intervention name(s): repaglinide; metformin; repaglinide and metformin combination tablet
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order; Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order; Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
Intervention MeSH terms: Metformin; Repaglinide
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Investigator)
Primary purpose: Treatment
An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face
Condition: Aged Skin
Study type: Interventional
Phase: Phase 4

Summary: 
      A randomised, multi-centre, parallel-group efficacy and safety study evaluating two and three
      initial treatment sessions of Restylane Skinboosters Vital Lidocaine in the face.
    

Detailed description: 
      Approximately 50 female subjects shall be treated with two or three initial treatment
      sessions including long-term follow-up 18 months after the initial treatment regimen.
      Efficacy and safety to be evaluated.
    

Intervention name(s): Restylane Vital Skinboosters Lidocaine
Intervention type(s): Device
Intervention MeSH terms: Lidocaine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment